Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11941179 | 1.00 | TAAR1 (0.51) | TAAR1ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL20385774 | 0.78 | TAAR1 (0.56) | TAAR1ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL485589 | 0.78 | TAAR1 (0.56) | TAAR1ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL1315541 | 0.78 | TAAR1 (0.56) | TAAR1ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL13787926 | 0.78 | TAAR1 (0.56) | TAAR1ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL485591 | 0.78 | TAAR1 (0.56) | TAAR1ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL12312814 | 0.78 | TAAR1 (0.56) | TAAR1ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL2848530 | 0.74 | TAAR1 (0.51) | TAAR1ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL2848529 | 0.74 | TAAR1 (0.51) | TAAR1ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL20289497 | 0.72 | TAAR1 (0.61) | TAAR1ALDH1A1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2161277-B1 | Asymmetric synthesis of peptides | UNIV READING (GB) | 2013-04-10 | — | — | EP | disclosed |
| EP-2161277-B1 | Asymmetric synthesis of peptides | UNIV READING (GB) | 2013-04-10 | — | — | EP | disclosed |
| US-8399612-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120190816-A9 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2012-07-26 | — | — | US | disclosed |
| US-20110275784-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING | 2011-11-10 | — | — | US | disclosed |
| US-8044173-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2011-10-25 | — | — | US | disclosed |
| US-8044173-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2011-10-25 | — | — | US | disclosed |
| US-8044173-B2 | Asymmetric synthesis of peptides | UNIVERSITY OF READING (GB) | 2011-10-25 | — | — | US | disclosed |
| EP-2161277-A2 | Asymmetric synthesis of peptides | University of Reading (GB) | 2010-03-10 | — | — | EP | disclosed |
| EP-2161277-A2 | Asymmetric synthesis of peptides | University of Reading (GB) | 2010-03-10 | — | — | EP | disclosed |
| US-20080281075-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080281075-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080281075-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1937708-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | THE UNIVERSITY OF READING (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007031698-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | UNIVERSITY OF READING (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275784-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | PTMS, NGLY1, QPCT | TAAR1 1041/4885ALDH1A1 4569/4885MAPT 4877/4885 |
| US-20080281075-A1 | ASYMMETRIC SYNTHESIS OF PEPTIDES | PTMS, NGLY1, QPCT | TAAR1 1041/4885ALDH1A1 4569/4885MAPT 4877/4885 |
| US-20120190816-A9 | ASYMMETRIC SYNTHESIS OF PEPTIDES | PTMS, NGLY1, QPCT | TAAR1 1041/4885ALDH1A1 4569/4885MAPT 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.